Comparative Immunogenicity of the Recombinant Receptor-Binding Domain of Protein S SARS-CoV-2 Obtained in Prokaryotic and Mammalian Expression Systems

The receptor-binding domain (RBD) of the protein S SARS-CoV-2 is considered to be one of the appealing targets for developing a vaccine against COVID-19. The choice of an expression system is essential when developing subunit vaccines, as it ensures the effective synthesis of the correctly folded ta...

Descripción completa

Detalles Bibliográficos
Autores principales: Merkuleva, Iuliia A., Shcherbakov, Dmitry N., Borgoyakova, Mariya B., Shanshin, Daniil V., Rudometov, Andrey P., Karpenko, Larisa I., Belenkaya, Svetlana V., Isaeva, Anastasiya A., Nesmeyanova, Valentina S., Kazachinskaia, Elena I., Volosnikova, Ekaterina A., Esina, Tatiana I., Zaykovskaya, Anna V., Pyankov, Oleg V., Borisevich, Sophia S., Shelemba, Arseniya A., Chikaev, Anton N., Ilyichev, Alexander A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8779843/
https://www.ncbi.nlm.nih.gov/pubmed/35062757
http://dx.doi.org/10.3390/vaccines10010096

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8779843/
https://www.ncbi.nlm.nih.gov/pubmed/35062757
http://dx.doi.org/10.3390/vaccines10010096

Ejemplares similares